Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR1923Y] to Cortactin
- Suitable for: WB, Flow Cyt
- Knockout validated
- Reacts with: Mouse, Rat, Human
Product nameAnti-Cortactin antibody [EPR1923Y]
See all Cortactin primary antibodies
DescriptionRabbit monoclonal [EPR1923Y] to Cortactin
Tested applicationsSuitable for: WB, Flow Cytmore details
Unsuitable for: IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human Cortactin aa 500-600 (C terminal). The exact sequence is proprietary.
- C6, MCF-7, Hela and A431 cell lysate and permeabilized MCF-7 cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab68438 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ICC: 1/100 - 1/250.
WB: 1/5000. Detects bands of approximately 75 and 80 kDa (predicted molecular weight: 80 kDa).
Is unsuitable for IHC-P or IP.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionContributes to the organization of the actin cytoskeleton and cell structure. Plays a role in the regulation of cell migration. Plays a role in the invasiveness of cancer cells, and the formation of metastases.
Sequence similaritiesContains 7 cortactin repeats.
Contains 1 SH3 domain.
DomainThe SH3 motif may mediate binding to the cytoskeleton.
modificationsTyrosine phosphorylation in transformed cells may contribute to cellular growth regulation and transformation.
Cellular localizationCytoplasm > cytoskeleton. Cell projection > lamellipodium. Cell projection > ruffle. Associated with membrane ruffles and lamellipodia.
- Information by UniProt
- Amplaxin antibody
- CTTN antibody
- EMS 1 antibody
Lane 1: Wild-type HAP1 cell lysate (40 µg)
Lane 2: Cortactin knockout HAP1 cell lysate (40 µg)
Lane 3: NIH3T3 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab68438 observed at 70 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab68438 was shown to specifically recognize Cortactin in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when Cortactin knockout samples were examined. Wild-type and Cortactin knockout samples were subjected to SDS-PAGE. Ab68438 and ab8245 (loading control to GAPDH) were diluted at 1/1000 and 1/10,000 dilution respectively and incubated overnight at 4C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes : Anti-Cortactin antibody [EPR1923Y] (ab68438) at 1/5000 dilution
Lane 1 : C6 cell lysate
Lane 2 : MCF-7 cell lysate
Lane 3 : Hela cell lysate
Lane 4 : A431 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 80 kDa
Observed band size: 80 kDa
Additional bands at: 75 kDa. We are unsure as to the identity of these extra bands.
Flow cytometric analysis of permeabilized MCF-7 cells using ab68438 1:30 dilution (pink) or a rabbit IgG (negative) (green).
ab68438 has been referenced in 1 publication.
- Sikorski K et al. A high-throughput pipeline for validation of antibodies. Nat Methods 15:909-912 (2018). PubMed: 30377371